Enhancing Immune Checkpoint Blockade Therapy of Genitourinary Malignancies by Co-targeting PMN-MDSCs

Overview

Journal Biochim Biophys Acta Rev Cancer

Publisher Elsevier

Specialties Biochemistry
Biophysics
Oncology

Date 2022 Mar 1

PMID 35227829

Authors

Xuemin Lu

Xin Lu

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint blockade (ICB) as a powerful immunotherapy has transformed cancer treatment. The application of ICB to genitourinary malignancies has generated substantial clinical benefits for patients with advanced kidney cancer or bladder cancer, yet very limited response to ICB therapy was observed from metastatic castration-resistant prostate cancer. The efficacy of ICB in rare genitourinary tumors (e.g. penile cancer) awaits results from ongoing clinical trials. A potential barrier for ICB is tumor-infiltrating polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) with their functions and mechanisms recently revealed. Preclinical studies suggest that successful therapeutic inhibition of PMN-MDSCs synergizes effectively with ICB to eradicate ICB-refractory genitourinary malignancies.

Citing Articles

YAP1 induces bladder cancer progression and promotes immune evasion through IL-6/STAT3 pathway and CXCL deregulation.

Sadhukhan P, Feng M, Illingworth E, Illingworth E, Sloma I, Ooki A J Clin Invest. 2024; 135(2.

PMID: 39630608 PMC: 11735109. DOI: 10.1172/JCI171164.

Evaluation of the clinical significance of lymphocyte subsets and myeloid suppressor cells in patients with renal carcinoma.

Li Y, Wu Z, Ni C, Li Y, Wang P Discov Oncol. 2024; 15(1):512.

PMID: 39347882 PMC: 11442913. DOI: 10.1007/s12672-024-01405-2.

Ferroptosis in cancer (Review).

Zeng L, Liu X, Geng C, Gao X, Liu L Oncol Lett. 2024; 28(1):304.

PMID: 38774452 PMC: 11106693. DOI: 10.3892/ol.2024.14437.

[Research Progress of Granulocytic Myeloid-derived Suppressor Cells  in Non-small Cell Lung Cancer].

Yang C, Zhu R, Zhang Y, Ying L, Wang J, Liu P Zhongguo Fei Ai Za Zhi. 2024; 27(1):65-72.

PMID: 38296627 PMC: 10895289. DOI: 10.3779/j.issn.1009-3419.2023.106.28.

Neutrophils resist ferroptosis and promote breast cancer metastasis through aconitate decarboxylase 1.

Zhao Y, Liu Z, Liu G, Zhang Y, Liu S, Gan D Cell Metab. 2023; 35(10):1688-1703.e10.

PMID: 37793345 PMC: 10558089. DOI: 10.1016/j.cmet.2023.09.004.

References

Alshetaiwi H, Pervolarakis N, McIntyre L, Ma D, Nguyen Q, Rath J . Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci Immunol. 2020; 5(44). PMC: 7219211. DOI: 10.1126/sciimmunol.aay6017. View

Thomas A, Necchi A, Muneer A, Tobias-Machado M, Tran A, Van Rompuy A . Penile cancer. Nat Rev Dis Primers. 2021; 7(1):11. DOI: 10.1038/s41572-021-00246-5. View

Kuasne H, Matos do Canto L, Aagaard M, Munoz J, De Jamblinne C, Marchi F . Penile Cancer-Derived Cells Molecularly Characterized as Models to Guide Targeted Therapies. Cells. 2021; 10(4). PMC: 8067406. DOI: 10.3390/cells10040814. View

Lu X, Horner J, Paul E, Shang X, Troncoso P, Deng P . Effective combinatorial immunotherapy for castration-resistant prostate cancer. Nature. 2017; 543(7647):728-732. PMC: 5374023. DOI: 10.1038/nature21676. View

Zhang H, Ye Y, Li M, Ye S, Huang W, Cai T . CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer. Oncogene. 2016; 36(15):2095-2104. DOI: 10.1038/onc.2016.367. View

Kawahara T, Kato M, Tabata K, Kojima I, Yamada H, Kamihira O . A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment. BMC Cancer. 2020; 20(1):919. PMC: 7519532. DOI: 10.1186/s12885-020-07410-2. View

Aggen D, Ager C, Obradovic A, Chowdhury N, Ghasemzadeh A, Mao W . Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses. Clin Cancer Res. 2020; 27(2):608-621. PMC: 7980495. DOI: 10.1158/1078-0432.CCR-20-1610. View

Grover A, Sanseviero E, Timosenko E, Gabrilovich D . Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic. Cancer Discov. 2021; 11(11):2693-2706. DOI: 10.1158/2159-8290.CD-21-0764. View

Hossain D, Pal S, Moreira D, Duttagupta P, Zhang Q, Won H . TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients. Clin Cancer Res. 2015; 21(16):3771-82. PMC: 4537814. DOI: 10.1158/1078-0432.CCR-14-3145. View

10.

Zhao Y, Peng X, Baldwin H, Zhang C, Liu Z, Lu X . Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model. Biochim Biophys Acta Mol Basis Dis. 2021; 1867(7):166151. DOI: 10.1016/j.bbadis.2021.166151. View

11.

Yang J, Yan C, Vilgelm A, Chen S, Ayers G, Johnson C . Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity. Cancer Immunol Res. 2020; 9(2):200-213. PMC: 7864868. DOI: 10.1158/2326-6066.CIR-20-0312. View

12.

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

13.

Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M . IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018; 559(7714):363-369. PMC: 6461206. DOI: 10.1038/s41586-018-0266-0. View

14.

Templeton A, McNamara M, Seruga B, Vera-Badillo F, Aneja P, Ocana A . Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014; 106(6):dju124. DOI: 10.1093/jnci/dju124. View

15.

Najjar Y, Rayman P, Jia X, Pavicic Jr P, Rini B, Tannenbaum C . Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α. Clin Cancer Res. 2016; 23(9):2346-2355. PMC: 5411325. DOI: 10.1158/1078-0432.CCR-15-1823. View

16.

Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, Arisa S . Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Clin Cancer Res. 2017; 23(17):5187-5201. PMC: 5723438. DOI: 10.1158/1078-0432.CCR-17-0741. View

17.

Guan Y, Xiong H, Feng Y, Liao G, Tong T, Pang J . Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. Prostate Cancer Prostatic Dis. 2020; 23(2):220-231. DOI: 10.1038/s41391-020-0209-3. View

18.

Si Y, Merz S, Jansen P, Wang B, Bruderek K, Altenhoff P . Multidimensional imaging provides evidence for down-regulation of T cell effector function by MDSC in human cancer tissue. Sci Immunol. 2019; 4(40). DOI: 10.1126/sciimmunol.aaw9159. View

19.

Subudhi S, Siddiqui B, Aparicio A, Yadav S, Basu S, Chen H . Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer. 2021; 9(10). PMC: 8524287. DOI: 10.1136/jitc-2021-002919. View

20.

Lopez-Bujanda Z, Haffner M, Chaimowitz M, Chowdhury N, Venturini N, Patel R . Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression. Nat Cancer. 2022; 2(8):803-818. PMC: 9169571. DOI: 10.1038/s43018-021-00227-3. View